Welcome to ClinicalInvestor: Making Biotech Investing Accessible
Biotech stocks are some of the most exciting — and volatile — investments in the market. A single FDA decision can send a stock up 200% or down 80% overnight. Yet most of the tools and data that professional biotech investors rely on are locked behind expensive terminals and paywalls. ClinicalInvestor was built to change that.
What We Built
ClinicalInvestor is a free platform designed specifically for retail investors interested in clinical-stage biotech companies. We provide four core tools: a Catalyst Calendar that tracks every upcoming FDA decision and clinical trial readout, detailed Company Profiles breaking down pipeline assets and competitive positioning, Educational Guides that explain biotech investing concepts in plain English, and a Trial Translator that uses AI to convert complex clinical data into investor-friendly summaries.
Why This Matters
The biotech sector moves on data. PDUFA dates, Phase 3 readouts, Advisory Committee votes — these are the events that drive 20-60% stock moves. But finding and interpreting this information requires navigating FDA databases, SEC filings, ClinicalTrials.gov, and company press releases. We do that work so you can focus on making informed investment decisions.
Our Data Sources
Everything on ClinicalInvestor comes from official public sources. We pull PDUFA dates directly from FDA.gov, monitor ClinicalTrials.gov for trial updates, cross-reference SEC filings for material events, and track company investor relations for the latest pipeline developments. Every data point goes through our multi-step verification process before it appears on the site.
What Is Coming Next
We are actively building new features including an advanced stock screener with real-time filtering by PDUFA date proximity, trial phase, and therapeutic area. We are also expanding our educational content with weekly guides on topics like reading clinical trial data, understanding FDA approval pathways, and building a biotech portfolio. Stay tuned by subscribing to our newsletter.